An additional 160,000 Australians are now able to access subsidised COVID-19 antiviral treatments after the federal government expanded eligibility criteria under the Pharmaceutical Benefits Scheme (PBS).
From today, people in their 60s with one risk factor for severe COVID-19 can get a prescription for Pfizer's oral antiviral treatment, Paxlovid, which was previously only available to people in this age group with two risk factors.
